Recent

% | $
Quotes you view appear here for quick access.

SS&C Technologies Holdings, Inc. Message Board

jathman 73 posts  |  Last Activity: May 21, 2015 7:12 PM Member since: Apr 4, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Rare Air

    by ieddyeddy May 14, 2015 7:18 PM
    jathman jathman May 14, 2015 11:58 PM Flag

    Stingily hoarded cash from shareholders for himself. Years to come? Dude, he does an offering at least once every year and 3rd R/S going to be needed if he can't drum up some interest in the stock. If you believe what he says about having enough cash then you might want to rewind some prior conference calls where he said the same exact thing then diluted shortly after. No debt? True. Companies that dilute often don't have debt. Besides, who is going to lend $ to a lying sleezeball who hasnt spun a profit in 18 years because he can't sell anything but lies?

  • Reply to

    Reverse Split Imminent

    by darkware98 May 13, 2015 9:59 PM
    jathman jathman May 13, 2015 11:17 PM Flag

    Business days not calendar days. 180 days not 90 days. Can get additional 180 day extension.

    It's a verified fact!

  • Reply to

    enough cash to last.

    by timeforacrash May 13, 2015 9:10 AM
    jathman jathman May 13, 2015 11:01 PM Flag

    18 years - 2 decades not 1

  • Reply to

    enough cash to last.

    by timeforacrash May 13, 2015 9:10 AM
    jathman jathman May 13, 2015 11:00 PM Flag

    eddy, are your ridiculously stupid comments just some sort of juvenile prank to get people riled up or are you really that fresking stupid? You could poll every single shareholder in CYCC history and you wouldn't get a single one of them to say that Spiro has done the right thing. He's made terrible decisions and has flat out lied to his shareholders. And the company is in great shape? yeah, such great shape that they will have to dilute again within a year and conduct a 3rd reverse split and they have no partner or approved drug in 18 years!!!!. Spiro has already provided a -99.5% return to initial investors. How many years do you get to be a developmental drug company? I guess a lifetime if Spiro is your CEO.

  • Reply to

    Haven't listened to Spiro's blabber

    by jathman May 12, 2015 10:46 PM
    jathman jathman May 13, 2015 7:42 AM Flag

    Rare air? Not with Spiro.

  • But read the 8K. Sure sounds like Spiro wants to take a run at AML with 065. If he there is a R/S and he announces an AML trial (presumably without a partner), I will short as many shares as I can afford to.

  • Reply to

    earnings release. a " non-event "

    by timeforacrash May 12, 2015 2:51 PM
    jathman jathman May 12, 2015 4:39 PM Flag

    If a tree falls in a forest...

    All the things you say are valid, I saw the SPPI news and thought the same thing. Dart and Sabby should apply major heat. Even if they issued a PR indicating they were seeking changes the PPS would at least temporarily pop like SPPI. Where's Bill Ackman? Oh yeah, Ackman wouldnt touch this from the long side.

    IMO Spiro is running a fraud. Keep hope alive but take as long as possible. He's been CEO since 1997. Prior to taking the company public through a reverse merger, he was milking private equity. Nearly 20 years of sucking the teets of others and not one licensing deal or one product approved. But hundreds of bi-weekly paychecks and potentially profiting from short selling too.

  • Reply to

    Bravo Spiro Bravo!

    by jathman May 11, 2015 12:29 PM
    jathman jathman May 11, 2015 7:33 PM Flag

    When he's not busy sailing the Mediterranean, yes.

  • Reply to

    Bravo Spiro Bravo!

    by jathman May 11, 2015 12:29 PM
    jathman jathman May 11, 2015 4:06 PM Flag

    He has got to be in on the short side. No other logical explanation for his indifference to share price erosion.

  • Those that bought the secondary are already down 25%.

    Spiro = the kiss of death.

  • Reply to

    Did anyone notice that

    by duedilligence213 May 10, 2015 1:26 PM
    jathman jathman May 10, 2015 10:59 PM Flag

    What does that say about Spiro? He can't even get the placement touts to issue a buy recommendation. Pathetic.

  • Reply to

    Where did the merry new band of pumpers go?

    by jathman May 6, 2015 10:21 PM
    jathman jathman May 10, 2015 12:50 PM Flag

    The word is "good efficacy"? I seem to recall that 70% of patients were dead after 6 months. Now, this may be due to a combo of very sick elderly patients coupled with poor trial design, but the only thing we heard is that sapa patients weren't disadvantaged as compared to control. I don't recall anyone saying "good efficacy". Now, there may be some hope if the few survivors live longer on sapa + daco vs daco alone, but let's face it, the interim analysis grade was a solid "F". And the CEO IMO is an absolute #$%$. That phase 2b has been talked about ad nauseum. Keep in mind Spiro has already run multiple phase 2s MDS. And if 065 is the crown jewel and CDK research is why the company was founded, what in the hell has Spiro been doing since 1997? Interesting how he pulls 065 out of the closet after sapa fails interim futlity. A sucker is born every minute and he knows it. There is better chance of making money by pitching dimes into soda bottles at the local carnival than with Spiro. That's because even carnival management guys who ripoff kids have more ethics than Spiro.

  • Reply to

    Sapacitabine Approval Window

    by ieddyeddy May 7, 2015 12:52 PM
    jathman jathman May 8, 2015 12:29 AM Flag

    Well actually I think it is a time for words. Yes the independent DSMB does advise the principal investigator and/or sponsor to the degree it can without compromising the integrity of the trial, however the DSMB is appointed by the investigator or sponsor. Therefore the DSMB is not "the FDA" and nor does the FDA "pick" the DSMB. Rather the FDA sets guidelines for DSMBs and the #1 priority of the DSMB is the "S" or safety. It is not the DEMB where "E" is efficacy.

  • Reply to

    Sapacitabine Approval Window

    by ieddyeddy May 7, 2015 12:52 PM
    jathman jathman May 7, 2015 7:15 PM Flag

    Where and when did "the FDA" explicitly say there is good efficacy or a favorable toxicity profile or ease of administration? If you can point readers or media to such value statements made by the FDA then you would presumably help the pps.

  • Such unbridled enthusiasm by cyc065baby there for a while. Leave it to Spiro to suck the life out of the party.

  • Reply to

    Why is everyone here so mad at the CEO?

    by cyc065allthewaybaby Apr 30, 2015 10:35 AM
    jathman jathman May 1, 2015 9:39 PM Flag

    And just when is that 2b trial going to start? When was the last phase 2 completed? Weren't final results shared at ASH 2012? Might need to update the 2b feasibility study.

  • Reply to

    Why is everyone here so mad at the CEO?

    by cyc065allthewaybaby Apr 30, 2015 10:35 AM
    jathman jathman May 1, 2015 9:30 PM Flag

    I agree. I believe he has been "in" on all the shorting of secondaries. Remember his Greek Northwestern buddy is a principal at Aspire. I also believe he purposefully does not aggressively advance the "pipeline" because the "company" is likely just a fraudulent shell designed to enrich a select few. The longer the better. You tell me. Why does a company with ~ 15 "employees" need a CFO and a Controller? Maybe they should add a VP of Finance too! What does the Director of Business Development do? Not only can't Spiro ink any deals you have another resource who God only knows also does what? That website hasn't been updated in a decade (no mobile site either) and almost all the white papers are old as the hills. This is the seedy underbelly of "biotech". Get a hold of a compound (especially for oncology), sell hope by preying on heartstrings and run the dilution engine for as long as possible. Squeeze every last nickel. Everyone wants to know why the Board doesn't do anything. Maybe they are walking the same money trail.

  • jathman jathman Apr 26, 2015 9:35 AM Flag

    This seems to happen a lot with secondaries, not limited to STEM. My bet is that it was Maxim. I bet they shorrted into the secondary.

  • The buyers of the secondary purchase 1 share at $0.70 and warrant for 0.75 share at $0.85.

    This means they pay $1.55 for 1.75 shares which = $0.8857 per share. So expect to see a run back to $1

    Maxim likely shorted ahead of the secondary which help facilitate the drop from $1 down to low .80s. They likely covered yesterday. Now they will help run it up for themselves and any institutional buyers of the secondary. So they likely "get paid" 3 ways - U/W fee, short into secondary, long after cover.

SSNC
59.30-0.78(-1.30%)May 26 4:00 PMEDT